Alfresa Holdings Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARHCF research report →
Companywww.alfresa.com
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies.
- CEO
- Ryuji Arakawa
- IPO
- 2020
- Employees
- 12,517
- HQ
- Tokyo, JP
Price Chart
Valuation
- Market Cap
- $2.16B
- P/E
- 9.67
- P/S
- 0.13
- P/B
- 0.80
- EV/EBITDA
- 4.80
- Div Yield
- 3.06%
Profitability
- Gross Margin
- 7.02%
- Op Margin
- 1.17%
- Net Margin
- 1.34%
- ROE
- 8.48%
- ROIC
- 4.28%
Growth & Income
- Revenue
- $3.12T · 5.49%
- Net Income
- $42.01B · 53.38%
- EPS
- $231.68 · 57.03%
- Op Income
- $36.25B
- FCF YoY
- 211.88%
Performance & Tape
- 52W High
- $11.87
- 52W Low
- $11.87
- 50D MA
- $11.87
- 200D MA
- $11.87
- Beta
- -0.12
- Avg Volume
- 412
Get TickerSpark's AI analysis on ARHCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ARHCF Coverage
We haven't published any research on ARHCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARHCF Report →